A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

PubWeight™: 1.04‹?› | Rank: Top 15%

🔗 View Article (PMC 2230393)

Published in Mol Med on December 01, 1998

Authors

F M Batliwalla1, B A Bateman, D Serrano, D Murray, S Macphail, V C Maino, J C Ansel, P K Gregersen, C A Armstrong

Author Affiliations

1: North Shore University Hospital-NYU School of Medicine, 350 Community Drive, Manhasset, New York, USA.

Articles citing this

Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28

Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol (2009) 1.20

Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther (2009) 1.18

Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol (2008) 1.17

Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther (2008) 1.16

p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol (2007) 1.09

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther (2012) 1.03

Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol (2003) 0.96

Oncolysis by paramyxoviruses: preclinical and clinical studies. Mol Ther Oncolytics (2015) 0.95

Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther (2010) 0.88

Safety and clinical usage of newcastle disease virus in cancer therapy. J Biomed Biotechnol (2011) 0.87

"First do no harm" and the importance of prediction in oncology. EPMA J (2010) 0.86

Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. J Mol Med (Berl) (2010) 0.85

Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making? Future Virol (2013) 0.79

Detection of free peritoneal cancer cells in gastric cancer using cancer-specific Newcastle disease virus. J Gastrointest Surg (2009) 0.78

Novel oncolytic viral therapies in patients with thoracic malignancies. Oncolytic Virother (2016) 0.78

Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Biomedicines (2016) 0.77

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Mol Ther Oncolytics (2014) 0.77

Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. Oncolytic Virother (2017) 0.75

Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition. Biomark Cancer (2016) 0.75

The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications. Oncolytic Virother (2015) 0.75

Articles cited by this

Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Cutaneous melanoma. N Engl J Med (1991) 5.92

Expression of two T cell receptor alpha chains: dual receptor T cells. Science (1993) 3.54

Clonal predominance of T cell receptors within the CD8+ CD45RO+ subset in normal human subjects. J Immunol (1993) 2.73

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10

A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg (1981) 2.09

Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg (1991) 2.06

Oligoclonal CD8+ T cells are preferentially expanded in the CD57+ subset. J Immunol (1995) 1.47

Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst (1994) 1.47

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT. Cancer (1965) 1.43

Biostatistical basis of elective node dissection for malignant melanoma. Ann Surg (1977) 1.27

Characterization of human T cells reactive with the Mycoplasma arthritidis-derived superantigen (MAM): generation of a monoclonal antibody against V beta 17, the T cell receptor gene product expressed by a large fraction of MAM-reactive human T cells. J Exp Med (1991) 1.26

Prognostic value of lymph node dissection in malignant melanoma. Arch Surg (1980) 1.24

Oligoclonality in the human CD8+ T cell repertoire in normal subjects and monozygotic twins: implications for studies of infectious and autoimmune diseases. Mol Med (1995) 1.20

Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst (1988) 1.20

Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surg (1982) 1.15

Interleukin 10 production by human melanoma. Clin Cancer Res (1996) 1.12

A method for production of antibodies to human T-cell receptor beta-chain variable regions. Proc Natl Acad Sci U S A (1991) 1.11

Cutaneous malignant melanoma: prognostic guidelines for physicians and patients. CA Cancer J Clin (1982) 1.01

A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother (1992) 0.98

Immunobiology and immunotherapy of melanoma. Curr Opin Oncol (1995) 0.96

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol (1997) 0.96

Adjuvant therapy for melanoma. Curr Opin Oncol (1997) 0.96

Vaccine therapy for malignant melanoma. CA Cancer J Clin (1996) 0.93

New developments in the virus therapy of cancer: a historical review. Intervirology (1993) 0.93

Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J Clin Invest (1997) 0.92

Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Regul (1988) 0.90

In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. Eur J Cancer (1991) 0.90

The role of adjuvant therapy in melanoma management. Cancer (1995) 0.90

Oligoclonality in the CD8+ T-cell population. Analysis using a multiplex PCR assay for CDR3 length. Ann N Y Acad Sci (1995) 0.89

Immunotherapy and gene therapy of cancer. Adv Surg (1995) 0.88

Malignant melanoma: prognostic indicators. Mayo Clin Proc (1997) 0.88

Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis, and treatment. CA Cancer J Clin (1996) 0.86

Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer (1997) 0.85

Cancer vaccines get a shot in the arm. Science (1993) 0.85

Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer (1994) 0.84

A method for producing monoclonal antibodies to human T-cell-receptor beta-chain variable regions. Proc Natl Acad Sci U S A (1993) 0.84

Malignant melanoma. Inflammatory mononuclear cell infiltrates in cerebral metastases during concurrent therapy with viral oncolysate. Cancer (1986) 0.83

Viral oncolysates as human tumor vaccines. Int Rev Immunol (1991) 0.81

Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer (1977) 0.81

T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. J Immunother Emphasis Tumor Immunol (1994) 0.80

Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol (1993) 0.80

Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer (1977) 0.79

Reduced lymphocyte subpopulations in patients with advanced or disseminated melanoma. J Am Acad Dermatol (1993) 0.79

Deaths from melanoma--United States, 1973-1992. MMWR Morb Mortal Wkly Rep (1995) 0.77

In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells. Cancer Immunol Immunother (1993) 0.76

Articles by these authors

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med (1999) 7.77

Questionnaire on the perceptions of patients about total hip replacement. J Bone Joint Surg Br (1996) 7.44

Questionnaire on the perceptions of patients about total knee replacement. J Bone Joint Surg Br (1998) 7.20

RJR Nabisco's cartoon camel promotes camel cigarettes to children. JAMA (1991) 7.07

Quantitation of intraepithelial lymphocytes in human jejunum. Gut (1971) 6.18

Variations in mortality after emergency laparotomy: the first report of the UK Emergency Laparotomy Network. Br J Anaesth (2012) 4.61

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods (2001) 4.25

A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet (2001) 4.17

Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest (1997) 4.01

High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. Genes Immun (2006) 3.86

Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest (1994) 3.16

Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood (1995) 3.12

Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol (1996) 3.03

The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum (1999) 2.92

RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun (2002) 2.88

Repulsive axon guidance: Abelson and Enabled play opposing roles downstream of the roundabout receptor. Cell (2000) 2.88

Clonal predominance of T cell receptors within the CD8+ CD45RO+ subset in normal human subjects. J Immunol (1993) 2.73

Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med (1990) 2.62

Validation of the Edinburgh Postnatal Depression Scale (EPDS) in non-postnatal women. J Affect Disord (1996) 2.62

Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry (2010) 2.57

The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun (2005) 2.47

Pricing strategy to promote fruit and vegetable purchase in high school cafeterias. J Am Diet Assoc (1997) 2.45

Molecular diversity of HLA-DR4 haplotypes. Proc Natl Acad Sci U S A (1986) 2.40

A controlled study of the onset, duration and prevalence of postnatal depression. Br J Psychiatry (1993) 2.38

Fatal pulmonary emboli in hospitalized patients. An autopsy study. Arch Intern Med (1988) 2.37

Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome. Lancet (1991) 2.31

A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun (2002) 2.21

Structure and function of the small intestine in dermatitis herpetiformis. Br J Dermatol (1967) 2.20

Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol (1998) 2.12

Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods (1998) 2.10

Operational criteria for the determination of suicide. J Forensic Sci (1988) 2.09

Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int (1995) 2.06

Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol (2010) 2.02

The role of calcium ions in initiating transformation of lymphocytes. Nature (1974) 2.01

Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis (2000) 1.81

Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant (2003) 1.80

HIV seroprevalence in a London same-day testing clinic. AIDS (1994) 1.78

Intestinal tuberculosis: experience at a Canadian teaching institution. Am J Med (1977) 1.78

The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet (2002) 1.77

Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation. Genes Immun (2004) 1.77

Early childhood music education and predisposition to absolute pitch: teasing apart genes and environment. Am J Med Genet (2001) 1.71

T cell receptor V-segment frequencies in peripheral blood T cells correlate with human leukocyte antigen type. J Exp Med (1991) 1.69

Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery (1996) 1.67

Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology (2011) 1.67

Is dieting good for you?: Prevalence, duration and associated weight and behaviour changes for specific weight loss strategies over four years in US adults. Int J Obes Relat Metab Disord (1999) 1.67

Retracted Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science (2001) 1.67

Relationship between enhanced turnover of phosphatidylinositol and lymphocyte activation by mitogens. Biochem J (1975) 1.67

Membrane binding of peptides containing both basic and aromatic residues. Experimental studies with peptides corresponding to the scaffolding region of caveolin and the effector region of MARCKS. Biochemistry (2000) 1.67

Dieting status and its relationship to eating and physical activity behaviors in a representative sample of US adolescents. J Am Diet Assoc (1998) 1.67

Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun (2005) 1.66

Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology (2008) 1.66

Adult coeliac disease in hyposplenic patients. Lancet (1970) 1.63

Commitment to X inactivation precedes the twinning event in monochorionic MZ twins. Am J Hum Genet (1998) 1.61

Comparison of measures to assess outcomes in total hip replacement surgery. Qual Health Care (1996) 1.60

Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol (1995) 1.59

A diffuse infiltrative CD8 lymphocytosis syndrome in human immunodeficiency virus (HIV) infection: a host immune response associated with HLA-DR5. Ann Intern Med (1990) 1.57

The intrinsic electrostatic potential and the intermediate ring of charge in the acetylcholine receptor channel. J Gen Physiol (2000) 1.56

The expression of functional LPS receptor proteins CD14 and toll-like receptor 4 in human corneal cells. Invest Ophthalmol Vis Sci (2001) 1.55

Analysis of the molecular specificities of anti-class II monoclonal antibodies by using L cell transfectants expressing HLA class II molecules. J Immunol (1988) 1.54

IFN-beta 2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. J Immunol (1989) 1.54

Risks and benefits of prophylaxis against venous thromboembolism in orthopaedic surgery. J Bone Joint Surg Br (2000) 1.53

Mitogen activation of human chronic lymphatic leukemia cells. I. Synthesis and secretion of immunoglobulin. J Immunol (1977) 1.52

Febrile urinary infection in the institutionalized elderly. Am J Med (1996) 1.47

Oligoclonal CD8+ T cells are preferentially expanded in the CD57+ subset. J Immunol (1995) 1.47

Instant recognition: the genetics of pitch perception. Am J Hum Genet (1998) 1.47

The significance of spinal cord compression as the initial manifestation of lymphoma. Neurosurgery (1993) 1.47

Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int (1996) 1.46

Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol (1999) 1.45

CD4(+)CD8(dim) T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens. Eur J Immunol (2001) 1.43

Inhibitory and anti-inflammatory effects of the Helicobacter pylori-derived antimicrobial peptide HPA3NT3 against Propionibacterium acnes in the skin. Br J Dermatol (2014) 1.43

Adrenal myelolipomatous nodules mimicking adrenal neoplasms: report of three cases. Can J Surg (1989) 1.43

Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun (2007) 1.43

Computed tomographic colonography (CTC) performance: one-year clinical follow-up. Clin Radiol (2006) 1.42

An outburst from a massive star 40 days before a supernova explosion. Nature (2013) 1.42

Urinary antibody level and survival in bacteriuric institutionalized older subjects. J Am Geriatr Soc (1998) 1.40

Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation. Leukemia (2004) 1.39

The value of an elastic tissue stain in detecting venous invasion in colorectal cancer. J Clin Pathol (2004) 1.37

Natural history of anterior knee pain: a 14- to 20-year follow-up of nonoperative management. J Pediatr Orthop (1998) 1.36

Absolute pitch: prevalence, ethnic variation, and estimation of the genetic component. Am J Hum Genet (1999) 1.33

Imputation strategies for missing data in a school-based multi-centre study: the Pathways study. Stat Med (2001) 1.33

Rheumatoid arthritis: a view of the current genetic landscape. Genes Immun (2008) 1.32

Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technol Assess (1998) 1.32

Evidence for the validity of a patient-based instrument for assessment of outcome after revision hip replacement. J Bone Joint Surg Br (2001) 1.30

Loss to follow-up: does it matter? Lancet (1995) 1.30

Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest (1994) 1.29

Immunofluorescence analysis of T-cell responses in health and disease. J Clin Immunol (2000) 1.29

Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol (1996) 1.29

Bacteriophage resistance in Bacillus subtilis 168, W23, and interstrain transformants. J Bacteriol (1976) 1.26

Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer (2006) 1.25

Prognosis in colon cancer: a pathologic reassessment. Arch Surg (1975) 1.25

Subchronic toxicity of chlorine dioxide and related compounds in drinking water in the nonhuman primate. Environ Health Perspect (1982) 1.23

Interpretation of patient-reported outcomes for hip and knee replacement surgery: identification of thresholds associated with satisfaction with surgery. J Bone Joint Surg Br (2012) 1.22

Analysis of DR beta and DQ beta chain cDNA clones from a DR7 haplotype. J Immunol (1986) 1.22

Oligoclonality in the human CD8+ T cell repertoire in normal subjects and monozygotic twins: implications for studies of infectious and autoimmune diseases. Mol Med (1995) 1.20

Provision of primary total hip replacement surgery. Lancet (1999) 1.20

Clonotypic structure of the human CD4+ memory T cell response to cytomegalovirus. J Immunol (2001) 1.19

Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS (2001) 1.19

MARCKS, membranes, and calmodulin: kinetics of their interaction. Biochim Biophys Acta (1998) 1.19

Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant (2012) 1.18